Pharmaceutical company engaged in the discovery and development of proprietary prodrugs
FDA regulation of opioid abuse deterrent formulations
H.R. 2430 (FDA Reauthorization Act of 2017), provisions relating to drugs
H.R. 2025 (Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017), all provisions Prodrug therapies and improving abuse deterrence and consumer safety
Anti-opioid abuse legislation
PHA - Pharmacy HCR - Health Issues
34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 19 - Office of Natl Drug Control Policy (NDCP) 1 - SENATE 10 - Vice President of the U.S. 12 - White House Office 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 19 - Office of Natl Drug Control Policy (NDCP) 1 - SENATE 10 - Vice President of the U.S. 12 - White House Office
ARENTFOX SCHIFF LLP
1717 K Street, NW, Washington, DC, 20006, US
PHILIP ENGLISH NORMAN FREDERICK LENT PHILIP ENGLISH NORMAN FREDERICK LENT SONJA NESBIT